Steven Brown, DO
Endocrinology, Diabetes & Metabolism · Layton, UTNPI 1649615873
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,684 of the $104,951 with a category attached, or 78.8%. 53 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 51.7% of the total. 2025 is the largest year on record at $60,428, more than ten times the $1,413 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 713 payments — averaging $147.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$54K
- Corcept Therapeutics$30K
- Ascendis Pharma Endocrinology Inc$13K
- Novo Nordisk$1K
- Abbott$963
- Amgen$856
- plus $5K from 47 others
What the payments were for
- Speaking & faculty fees$82,68479%
- Travel & lodging$10,17310%
- Food & beverage$12,06011%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,951 in reported general payments places this provider in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 12 | $260,864 |
| OzempicSemaglutide | 129 | $182,120 |
| TrulicityDulaglutide | 62 | $109,200 |
| JardianceEmpagliflozin | 58 | $93,869 |
| MounjaroTirzepatide | 62 | $89,294 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $52,268 |
| FarxigaDapagliflozin Propanediol | 40 | $51,434 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $39,213 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $38,668 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 60 | $37,810 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $28,723 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $18,972 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $14,597 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $11,316 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 22 | $9,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $29,551 | $260,86412 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $825 | $198,494124 claims |
| Novo NordiskOzempic | $1,053 | $182,120129 claims |
| Boehringer IngelheimJardiance | $237 | $93,86958 claims |
| AstraZenecaFarxiga | $127 | $51,43440 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $54,301 | $39,21322 claims |
| AbbVieSynthroid | $215 | $4,02643 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $3,159317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in Layton
- Khaldoun Al RayessLayton$9K
- Eliot BrintonSalt Lake City$733K
- Claudia FishPark City$286K
- Alireza Falahati-NiniSalt Lake City$241K
- Timothy GrahamSandy$90K
- Jack WahlenOgden$70K
- Mohammed NizamProvo$54K
- Shahzad AhmadSalt Lake City$25K
- Priya KrishnamurthySt George$22K
- Vishnu SundareshSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.